J&J beats estimates as stronger dollar impacts guidance

19 July 2022
johnson_big

US healthcare conglomerate Johnson & Johnson (NYSE: JNJ) beat estimates for sales and earnings figures with its second quarter 2022 results.

J&J’s sales rose 3% to $24.02 billion, where analysts had expected a figure of around $23.77 billion, according to IBES data from Refinitiv. Revenue from the Pharmaceutical division rose particularly steeply, with operational sales growth of more than 12% in the unit.

On an adjusted basis, the company earned $2.59 per share, beating estimates of $2.54 per share and up by more than 4% on the comparable quarter of 2021.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Company News Directory

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical